PolyPeptide Group AG PPGN.SW Stock
PolyPeptide Group AG Price Chart
PolyPeptide Group AG PPGN.SW Financial and Trading Overview
| PolyPeptide Group AG stock price | 31.6 CHF |
| Previous Close | 22.36 CHF |
| Open | 22.24 CHF |
| Bid | 22.36 CHF x N/A |
| Ask | 22.4 CHF x N/A |
| Day's Range | 22.24 - 22.52 CHF |
| 52 Week Range | 17.44 - 78.65 CHF |
| Volume | 2.34K CHF |
| Avg. Volume | 65.69K CHF |
| Market Cap | 741.34M CHF |
| Beta (5Y Monthly) | 0.927387 |
| PE Ratio (TTM) | 97.304344 |
| EPS (TTM) | -1.55 CHF |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | April 28, 2022 |
| 1y Target Est | 24.02 CHF |
PPGN.SW Valuation Measures
| Enterprise Value | 757.42M CHF |
| Trailing P/E | 97.304344 |
| Forward P/E | 27.974998 |
| PEG Ratio (5 yr expected) | 1.15 |
| Price/Sales (ttm) | 2.6384184 |
| Price/Book (mrq) | 1.7474817 |
| Enterprise Value/Revenue | 2.696 |
| Enterprise Value/EBITDA | 22.915 |
Trading Information
PolyPeptide Group AG Stock Price History
| Beta (5Y Monthly) | 0.927387 |
| 52-Week Change | -67.73% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 78.65 CHF |
| 52 Week Low | 17.44 CHF |
| 50-Day Moving Average | 22.33 CHF |
| 200-Day Moving Average | 26.41 CHF |
PPGN.SW Share Statistics
| Avg. Volume (3 month) | 65.69K CHF |
| Avg. Daily Volume (10-Days) | 26.41K CHF |
| Shares Outstanding | 33.13M |
| Float | 13.16M |
| Short Ratio | N/A |
| % Held by Insiders | 59.66% |
| % Held by Institutions | 29.33% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 1.2199 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 2.76% |
| Operating Margin (ttm) | 4.45% |
| Gross Margin | 18.50% |
| EBITDA Margin | 11.76% |
Management Effectiveness
| Return on Assets (ttm) | 1.33% |
| Return on Equity (ttm) | 1.84% |
Income Statement
| Revenue (ttm) | 280.98M CHF |
| Revenue Per Share (ttm) | 8.52 CHF |
| Quarterly Revenue Growth (yoy) | 1.60% |
| Gross Profit (ttm) | 51.99M CHF |
| EBITDA | 33.05M CHF |
| Net Income Avi to Common (ttm) | 7.77M CHF |
| Diluted EPS (ttm) | 0.23 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 37.53M CHF |
| Total Cash Per Share (mrq) | 1.14 CHF |
| Total Debt (mrq) | 31.72M CHF |
| Total Debt/Equity (mrq) | 7.52 CHF |
| Current Ratio (mrq) | 2.619 |
| Book Value Per Share (mrq) | 12.807 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 5.46M CHF |
| Levered Free Cash Flow (ttm) | -72130496 CHF |
Profile of PolyPeptide Group AG
| Country | Switzerland |
| State | N/A |
| City | Baar |
| Address | Neuhofstrasse 24 |
| ZIP | 6340 |
| Phone | 41 435 020 580 |
| Website | https://www.polypeptide.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 1219 |
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the Americas, the Asia Pacific, and internationally. It focuses on peptide- and oligonucleotide-based therapies for pharma and biotech customers. The company also develops and manufactures active ingredients for therapies that range from the treatment of metabolic diseases, such as diabetes or obesity, as well as cancer and cardiovascular, or neurological disorders. In addition, it engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. Further, the company is involved in manufacturing peptides for commercially approved peptide therapeutics. Additionally, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. The company offers regulatory affair support services. It has a collaboration agreement with Numaferm for peptide development and production The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Q&A For PolyPeptide Group AG Stock
What is a current PPGN.SW stock price?
PolyPeptide Group AG PPGN.SW stock price today per share is 31.6 CHF.
How to purchase PolyPeptide Group AG stock?
You can buy PPGN.SW shares on the Swiss exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for PolyPeptide Group AG?
The stock symbol or ticker of PolyPeptide Group AG is PPGN.SW.
Which industry does the PolyPeptide Group AG company belong to?
The PolyPeptide Group AG industry is Drug Manufacturers-Specialty & Generic.
How many shares does PolyPeptide Group AG have in circulation?
The max supply of PolyPeptide Group AG shares is 32.97M.
What is PolyPeptide Group AG Price to Earnings Ratio (PE Ratio)?
PolyPeptide Group AG PE Ratio is now.
What was PolyPeptide Group AG earnings per share over the trailing 12 months (TTM)?
PolyPeptide Group AG EPS is -1.55 CHF over the trailing 12 months.
Which sector does the PolyPeptide Group AG company belong to?
The PolyPeptide Group AG sector is Healthcare.
PolyPeptide Group AG PPGN.SW included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| SPI TR SSHI | 15742.31 CHF 17911.38 USD |
-0.64
|
— — | 15736.19 CHF 17904.41 USD | 15818.07 CHF 17997.58 USD | — - | — — |
| NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
- {{ link.label }} {{link}}